Bone Drugs Need Label Changes on Use Duration, Panel Says

Bone drugs from Warner Chilcott Plc, Roche Holding AG, Merck & Co. and Novartis AG need labeling changes to reduce the risk of fractures, a U.S. panel said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.